Arrowhead Pharmaceuticals (ARWR) Cash & Equivalents (2016 - 2025)
Arrowhead Pharmaceuticals (ARWR) has disclosed Cash & Equivalents for 16 consecutive years, with $201.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents rose 274.18% year-over-year to $201.6 million, compared with a TTM value of $201.6 million through Dec 2025, up 274.18%, and an annual FY2025 reading of $226.5 million, up 120.62% over the prior year.
- Cash & Equivalents was $201.6 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $226.5 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $226.5 million in Q3 2025 and bottomed at $2.4 million in Q1 2021.
- Average Cash & Equivalents over 5 years is $109.6 million, with a median of $109.4 million recorded in 2022.
- The sharpest move saw Cash & Equivalents tumbled 99.07% in 2021, then skyrocketed 5708.33% in 2022.
- Year by year, Cash & Equivalents stood at $39.3 million in 2021, then skyrocketed by 415.13% to $202.2 million in 2022, then plummeted by 71.22% to $58.2 million in 2023, then fell by 7.43% to $53.9 million in 2024, then soared by 274.18% to $201.6 million in 2025.
- Business Quant data shows Cash & Equivalents for ARWR at $201.6 million in Q4 2025, $226.5 million in Q3 2025, and $129.8 million in Q2 2025.